Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

CDG Therapeutics (United States) | Researchclopedia

Back to institutions

CDG Therapeutics (United States)

River Forest, Illinoiscompany

156

Works

7,408

Citations

48

h-index

Top Research Topics

Chronic Lymphocytic Leukemia Research Lymphoma Diagnosis and Treatment Monoclonal and Polyclonal Antibodies Research

Top Researchers

Gary Cutter University of Alabama at Birmingham

1,140 works57,729 citationsh-index: 120

Recent Research

Efficacy of Ublituximab in People with Highly Active Relapsing Multiple Sclerosis

Hans-Peter Hartung,Derrick Robertson,et al.

20260 citations

Immunodeficiency and Autoimmune Disorders

PI3K/AKT/mTOR signaling in cancer

CAR-T cell therapy research

Advanced Breast Cancer Therapies

Acute Lymphoblastic Leukemia research

Multiple Sclerosis Research Studies

Chronic Myeloid Leukemia Treatments

Immunotherapy and Immune Responses

Glycosylation and Glycoproteins Research

M. Pappagallo Istituto Nazionale di Fisica Nucleare, Sezione di Ferrara

704 works36,712 citationsh-index: 94

Owen A. O’Connor Vesuvius (United Kingdom)

570 works20,677 citationsh-index: 66

Lee Jia Beijing Forestry University

436 works18,474 citationsh-index: 63

Charles E. Inturrisi American Orchid Society

266 works13,628 citationsh-index: 65

Edward A. Fox Northumbria University

784 works13,080 citationsh-index: 52

A novel artificial intelligence-based methodology to predict non-specific response to treatment

Clotilde Guidetti,Maurizio Fava,et al.

20252 citations

ENABLE: The First Phase 4 Observational Study for Patients with Relapsing MS Treated with Ublituximab in Real World Clinical Setting (P7-1.014)

Edward Fox,Jackie Parker,et al.

20251 citations

Five Years of Ublituximab in Relapsing Multiple Sclerosis: Additional Results from Open-label Extension of ULTIMATE I and II Studies (P11-1.006)

Bruce Cree,Edward A. Fox,et al.

20250 citations

No Association Between Decreases in Serum Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) and Serious Infections (SI) with Long-term Ublituximab (UBL) Treatment in Patients with Relapsing Multiple Sclerosis (RMS) (P7-1.017)

Lawrence Steinman,Edward Fox,et al.

20250 citations

Retrospective Evaluation of Infusion Tolerability: Ublituximab Real-world Observational Survey (ENAMOR) (P7-1.015)

Edward Fox,Peter Sportelli,et al.

20250 citations